Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
Stock Market Value: $9.32B ($43.13 per share)
Ownership: n/a
Average Cost: n/a
Activist Commentary: Fivespan Partners, LP is a San Francisco-based investment firm founded by Dylan Haggart and Sarah Coyne. Prior to Fivespan, Haggart and Coyne were partners at ValueAct Capital and most of the investment team is from ValueAct. Fivespan, named after the unique five-stone arched bridge in Haggart's hometown, views itself as a bridge between the market and companies. The firm prefers behind-the-scenes, collaborative and amicable activism, but it would resort to a proxy fight if it had no other choice. We believe that the firm would look for board seats in situations where it thinks it could add real value, but we do not expect Fivespan to pursue board representation as often as ValueAct does (i.e, roughly 50% of core portfolio positions). Haggart certainly has experience as a public company director. He served as a director of Seagate (2018 to the present) and Fiserv (2022 to 2024), at which he has delivered stellar returns over his tenures of 44.45% and 64.68%, respectively, versus 17.36% and 4.98% for the Russell 2000. Additionally, Haggart was an advisor to Seagate going back as far as 2016, over which time the company returned about 222%. Fivespan looks for high quality, idiosyncratic businesses with good, strategic assets. The firm does not advocate for the sale of its portfolio companies as a primary activist strategy, but like companies that people want to own. Accordingly, many of the firm's activist campaigns could end with a sale of the company, providing two paths to shareholder value. The fund is a drawdown structure that holds investments for at least three to five years, aims to have six to eight investments at a time and averages $100 million to $300 million in each investment.
Fivespan Partners has built a position in Qiagen NV and has engaged in conversations with management.
Qiagen is a Netherlands-incorporated life sciences tools firm, dual-listed in the U.S. and Germany. The company provides sample technologies to isolate and process DNA, RNA and proteins; assay technologies to prepare these biomolecules for analysis; and automation solutions to bring these processes together. The company has two primary end markets from which it derives a balanced share of its revenue: Molecular Diagnostics (health-care providers) and Life Sciences (pharma/biotech research and other lab applications). It operates in an extremely attractive and growing industry with high returns on invested capital (ROIC) and margins. Qiagen specifically enjoys a leading market position, has a great brand reputation and favorably derives about 90% of its sales from recurring consumables revenue, with the remainder from the sale of its instruments and related services, a razor-razorblade model. Despite its dual-listing and European heritage, Qiagen's chairman and CEO are based in the U.S., and it generated 52% of its FY24 sales in North America, 32% in Europe, the Middle East and Africa, and 16% in Asia.
Fivespan looks for high quality, idiosyncratic businesses with good, strategic assets, and Qiagen fits this thesis nicely – a high-quality health-care business in a growing industry with secular tailwinds. However, despite having a respected name and a strong market position, the company has struggled to create shareholder value post-Covid, delivering 1-, 3-, and 5-year returns of 1%, -6%, and 1%, respectively. While peers trade at around 15 times EV/EBITDA, and leaders like Danaher 20 times, Qiagen currently trades at around 13 times. This contrasts with the stock historically trading at a significant multiple to peers.
Management has done the hard things right: investing in R&D, listening to the customers, and protecting the company's industry-leading brand, growing its topline at a 5.3% compound annual growth rate from 2019 to 2024. Now there is an opportunity to grow even faster and in a more focused manner. In an attempt to empire-build, Qiagen has lost sight of the core business, investing a lot in the diagnostics business and other ventures when the life sciences business has a superior return on invested capital. There are three levers to create shareholder value here. First, management should invest in and around its core business to accelerate growth. Moreover, they should not keep their plan a secret but communicate it better to the market. Second, Qiagen can be run a lot tighter, leaving room for margin expansion. Currently running at a 25% operating margin, a more disciplined approach could achieve operating margins upward of 30%. Third, Qiagen's balance sheet could be optimized. Most of its peers have far more leverage and should, due to the recurring nature of the business, yet the company has $1.15 billion of cash and short-term investments, $1.39 billion of debt and no good acquisition targets on the horizon. By levering up, Qiagen could fund additional investments in its core business and buy back some of its own stock at attractive prices ahead of growth and margin improvements. It is not often that there are opportunities for both revenue growth and margin expansion at the same time. When you have a situation like that, it certainly makes sense to buy back your own shares ahead of it.
Based on its activist philosophies, we would expect that Fivespan has had a position in Qiagen for some time and has been trying to work with management behind the scenes. The firm is a quiet investor and does not publicize its positions (i.e., this is one of six current positions and the only one known publicly). We think the company may not be playing as amicably as Fivespan. An indication of this is that, perhaps in response to Fivespan's engagement, the company recently pre-announced a beat for its Q1 results and raised expectations regarding its margins, targeting above 30% for the year and over 31% ahead of its 2028 timeline. Qiagen also put out a press release describing its product pipeline, nothing new per se, but a clear sea change in terms of its management of investor communications and proactive strategic planning. There are several ways this can go. Management can agree to embrace Fivespan, who is not advocating for any real controversial actions – growth and margin improvement, the same thing management wants. Management can ignore but placate the investor by taking actions consistent with the plan that results in shareholder appreciation. Or management can ignore the firm and continue down the same road with a flat stock price performance. Given that we do not expect that Fivespan will aggressively pursue a board seat here, we think the first option is preferable, the second is tolerable and the third is unacceptable. Often the tone of an activist campaign depends not on the activist, but the response of the company. This scenario could be a perfect example of that.
As mentioned before, Fivespan appreciates businesses with several paths to shareholder value, one of them being strategic transactions. Qiagen is a highly attractive asset. In fact, pre-Covid, the company held discussions with several suitors regarding a potential transaction. In 2020, they agreed to an improved offer of 43 euros per share from Thermo Fisher Scientific, but the deal ultimately collapsed after Thermo failed to reach the two-thirds tender offer threshold, in part due to a Covid-induced run-up in the share price and vocal shareholders like Davidson Kempner coming out against the deal. Today, the business is just as strong, if not stronger, and FY25 EPS is expected to come in higher than it was in 2020. A sale is never Fivespan's first choice when making an investment. The firm will focus on the operational and allocation improvements available to create shareholder value but evaluate that against any potential acquisition offer the company may receive and advocate for what it thinks is best for shareholders. With strategic and respected assets – and with the stock trading slightly below the previous offer price from five years ago – an unsolicited offer for the company is not outside of the realm of possibility.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications. Based on the study findings, a multi-regional Phase 3 clinical trial (G-HOPE-001, NCT06238843) was launched in 2024 to further evaluate IBI343 as a safe and effective treatment option for patients with advanced G/GEJ AC. Gastric cancer remains one of the most common malignant tumors in the world. According to the GLOBOCAN 2022 statistics, it ranks as the fifth most common malignant tumor and the fifth leading cause of cancer-related death globally, with an estimated 970,000 new cases and 660,000 deaths annually. Each year, China reports 359,000 new cases and 260,000 deaths from gastric cancer, representing 37.0% and 39.4% of global totals, respectively, highlighting a significant unmet medical need. CLDN 18.2 is a tight junction protein expressed in differentiated epithelial cells on the gastric mucosa under normal physiological conditions. Previous studies have revealed that Claudin18.2 is highly expressed in multiple types of cancer, including gastric cancer (60-80%), pancreatic cancer (50%), esophageal carcinoma (30-50%), and lung cancer (40-60%). Targeting CLDN18.2 with monoclonal antibodies (mAbs) and ADCs represents a promising new approach for treating gastric cancer. This published study is a global, multicenter Phase 1 clinical trial ( identifier: NCT05458219) designed to evaluate the safety, tolerability and preliminary efficacy of IBI343 in patients with advanced solid tumors. Between October 26, 2022, and June 30, 2024, a total of 116 subjects with advanced G/GEJ adenocarcinoma were enrolled to receive IBI343 monotherapy (8 in escalation and 108 in expansion). IBI343 has demonstrated encouraging tumor response and survival benefit The study analyzed the efficacy data of evaluable subjects with high expression of CLDN18.2 (≥75% tumor cells with membranous staining intensity ≥2+ by IHC), in the two dose groups of 6 mg/kg and 8 mg/kg. At 6 mg/kg (N=31), 15 patients had partial responses (PR) including 9 patients with confirmed PRs and 1 patient awaiting confirmation. The confirmed ORR was 29.0% (95% CI: 14.2-48.0) and the disease control rate (DCR) was 90.3% (95% CI: 74.2-98.0). In 9 patients with confirmed response, the median duration of response (DoR) was 5.6 months (95% CI: 2.8-7.0). The median follow-up was 10.6 months (95% CI: 9.7-11.5) for PFS and OS. The median PFS was 5.5 months (95% CI: 4.1-7.0). OS data was not mature with the current median OS of 10.8 months (95% CI: 6.8-NC). After data cutoff, response of the remaining 1 patient was confirmed on July 26, 2024 and the confirmed ORR was updated to 32.3% (95% CI: 16.7-51.4). At 8 mg/kg (N=17), 17 patients with high expression of CLDN 18.2 were evaluable. Among them, 9 patients had PRs including 8 patients had confirmed PR. The confirmed ORR 47.1% (95% CI: 23.0-72.2), and the DCR was 88.2% (95% CI: 63.6-98.5). In eight patients with confirmed response, the median DoR was 5.7 months (95% CI: 2.7-NC). Of all G/GEJ adenocarcinoma patients with high CLDN18.2 expression treated at 8 mg/kg (N=19, including 1 patient from dose escalation and 18 patients from dose expansion), the median follow-up was 8.1 months (95% CI: 7.6-8.5) for PFS and OS. The median PFS was 6.8 months (95% CI: 2.8-7.5), and the median OS was not reached with events occurred in 36.8% patients. IBI343 also demonstrated superior safety Among all patients with G/GEJ adenocarcinoma (n=116, including 8 patients with gastric cancer from the dose escalation phase), 66.4% patients (77/116) had ≥3 grade TEAEs. The most common ≥3 grade TEAEs (≥35%) were neutrophil count decreased (28.4%), white blood cell count decreased (25.9%), and anemia (16.4%). There were very few grade ≥3 gastrointestinal adverse events, including only 1.7% of grade ≥3 nausea. No interstitial lung disease of any grade was reported. Treatment-related toxicity was alleviated with adequate supportive treatment, and the overall safety was tolerable. Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of subsequent Phase 3 trial, suggesting that IBI343 may become a new treatment option for patients with gastric cancer in the future. Professor Lin Shen, Corresponding Author, Leading Principal Investigator, from Beijing Cancer Hospital, said, "Following the eras of chemotherapy, targeted therapy and immunotherapy, ADCs have opened a new frontier in the treatment of gastrointestinal tumors. IBI343 is a new generation of Fc-silent anti-CLDN18.2 ADC that has shown encouraging clinical benefits and low gastrointestinal toxicity in Phase 1 studies. We look forward to the results of the Phase 3 study comparing IBI343 with standard treatment, aiming to ultimately reshape clinical practice, transform treatment paradigms, and usher in a new chapter in precision medicine." Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, said, "There is a huge unmet clinical need for the treatment of advanced gastric cancer. The Phase 1 study results of IBI343 in advanced gastric and gastroesophageal junction adenocarcinoma, now published in the top international journal, Nature Medicine, further verify the clinical value of IBI343 in this population. We will work with researchers worldwide to advance the multi-regional Phase 3 clinical trial (G-HOPE-001), with the goal of establishing a new paradigm in clinical diagnosis and treatment and ultimately benefiting gastric cancer patients around the world. We are also exploring the therapeutic potential of IBI343 in pancreatic cancer and other indications." About Gastric/ Gastroesophageal Junction Adenocarcinoma Gastric cancer is one of the most prevalent malignant tumors worldwide and a leading cause of cancer-related deaths globally. The 5-year survival rate of patients with metastatic gastric cancer is less than 5%[i]. China and Japan have the highest incidence rates of gastric cancer[ii]. Currently, the standard-of-care treatments for patients with advanced metastatic gastric cancer include a chemotherapy combination of fluoropyrimidine and platinum, as well as immune checkpoint inhibitor therapy. However, systemic therapy has limited efficacy in advanced gastric cancer. In particular, the prognosis for patients with third-line or higher gastric cancer is usually poor, with fewer treatment options and shorter survival expectations. The median survival time for these patients is only about 0.5 year[iii]. Claudin, a member of the tight junction molecule family, is a key structural and functional component of epithelial tight junctions. Among them, CLDN18.2 is normally buried in gastric mucosa, but the development of malignancy leads to disruption of tight junctions and exposure of CLDN18.2 epitopes on the membrane of tumor cells[iv]. CLDN18.2 is expressed in up to 80% of patients with gastric cancer. About IBI343（Anti CLDN18.2 ADC） IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell, the cytotoxic payload is released, resulting in DNA damage and ultimately apoptosis of the tumor cells. The released drug can also diffuse across the plasma membrane to reach and kill neighboring cells, resulting in a "bystander killing effect". As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in this Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric cancer and pancreatic cancer. The multi-regional Phase 3 clinical trial of IBI343 for advanced gastric / gastroesophageal junction adenocarcinoma is now recruiting patients (G-HOPE-001, NCT06238843). The relevant indication has been granted Breakthrough Therapy Designation (BTD) by China's NMPA . The multi-regional Phase 1 clinical trial of IBI343 for advanced pancreatic ductal adenocarcinoma is also enrolling patients (NCT05458219). This indication has received Fast Track Designation (FTD) from the U.S. FDA and been granted BTD by China's NMPA. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: Biologics does not recommend the use of unapproved drugs/indications. injection (Cyramza®), selpercatinib capsules (Retsevmo®) and pirtobrutinib tablets (Jayprica®) were developed by Eli Lilly and Company Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References [i] Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. May 2014;34(5):2079-85 [ii] Xu B, Wang JM. Epidemiological study of gastric cancer[J]. Chin J Cancer Prev Treat, 2006,13(1): 81-87. [iii] Chan WL, Lam KO, So TH, et al. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019;11:1758835919859990. [iv] Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634. View original content: SOURCE Innovent Biologics
USA Today
33 minutes ago
- USA Today
Trader Joe's adds 16 new stores to 'coming soon' list: See locations
Trader Joe's has added 16 new locations to its list of stores that are "coming soon!" The company operates stores across 42 states, leaving only Alaska, Hawaii, Montana, North Dakota, South Dakota, Wyoming, Mississippi, and West Virginia without locations Nakia Rohde, a spokesperson for the Monrovia, California-based company, said it adds to the "Store Openings" tab on its announcement page "almost every month." The company had announced 21 new locations the previous time USA TODAY surveyed the page in April. Since then, the company has opened six of the previously announced locations, including one in the Sherman Oaks neighborhood of Los Angeles, which is across the street from the already existing Riverside Drive store. Rohde told USA TODAY at the time that the company intends to keep both locations open, saying that the new store "is bigger and has an attached underground parking lot." Where are the new Trader Joe's locations? Here are the latest future locations Trader Joe's has announced:
New York Post
33 minutes ago
- New York Post
United Airlines warns profit still suffering from Newark chaos — but travel demand picking up
United Airlines said Wednesday travel demand has picked up since the beginning of July, thanks to less geopolitical and macroeconomic uncertainty. The Chicago-based airline, however, expects its earnings to suffer in the current quarter due to operational constraints at Newark airport near New York City — one of its largest hubs and among the busiest in the country. United reported a 6 percentage point acceleration in overall travel demand and a double-digit acceleration in business bookings in the third quarter from the prior quarter. 3 United expects its earnings to suffer in the current quarter due to operational constraints at Newark airport near New York City – one of its largest hubs and among the busiest in the country. REUTERS As a result, it now expects its full-year adjusted profit to come in the range of $9 a share to $11 a share. That compares with analysts' expectations of $10.04 a share. 'The world is less uncertain today than it was during the first six months of 2025 and that gives us confidence about a strong finish to the year,' United CEO Scott Kirby said in a statement. United's shares were down 1.6% in after-hours trading as its third-quarter profit estimate came in below Wall Street estimates. The company expects an adjusted profit in the range of $2.25 a share to $2.75 per share in the quarter to end-September. The midpoint of the forecast is $2.50 per share, compared with analysts' average estimate of $2.60, according to LSEG data. It estimates a hit of 0.9 percentage point in the third quarter, compared with a 1.2 percentage point impact in the second quarter, due to the operational issues at Newark airport. In April, United took an unusual step of offering two different earnings forecasts as President Trump's trade war dented consumer and business confidence, making it harder for carriers to predict their business. 3 Industry executives say travel demand has stabilized since April. Luiz C. Ribeiro for New York Post Weak pricing power Since then, industry executives say travel demand has stabilized. Passenger traffic in the US, however, is still down from a year ago, leading to a decline in airfares, government data shows. The improvements in booking trends encouraged rival Delta Air Lines last week to reinstate its full-year profit outlook. But the latest earnings reports show airlines are still grappling with weak pricing power. United's yield, or average revenue earned from each paying passenger, was down in all geographies in the second quarter. The weakness was most pronounced in the US domestic market. 3 'The world is less uncertain today than it was during the first six months of 2025 and that gives us confidence about a strong finish to the year,' United CEO Scott Kirby said in a statement. Getty Images Echoing Delta, United said it expects the industry's efforts to slash unprofitable flights to boost airfares in the second half of the year. United's second-quarter adjusted profit came in at $3.87 a share, topping analysts' expectations of $3.81 a share. The company will discuss its financial results on a call with analysts and investors on Thursday morning.
